Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 235

1.

Chest High-Resolution CT Findings of Microscopic Polyangiitis: A Japanese First Nationwide Prospective Cohort Study.

Suzuki A, Sakamoto S, Kurosaki A, Kurihara Y, Satoh K, Usui Y, Nanki T, Arimura Y, Makino H, Okada Y, Harigai M, Yamagata K, Sugiyama H, Dobashi H, Ishizu A, Tsuboi N, Usui J, Sada KE, Homma S; for Japan Research Committee of the Ministry of Health, Labour, and Welfare for Intractable Vasculitis and Research Committee of Intractable Renal Disease of the Ministry of Health, Labour, and Welfare of Japan.

AJR Am J Roentgenol. 2019 Apr 11:1-11. doi: 10.2214/AJR.18.20967. [Epub ahead of print]

PMID:
30973774
2.

Comparison of fluorescence optical imaging, ultrasonography and clinical examination with magnetic resonance imaging as a reference in active rheumatoid arthritis patients.

Hirano F, Yokoyama-Kokuryo W, Yamazaki H, Tsutsumino M, Sakai R, Satoh S, Kimura T, Tojo N, Kohsaka H, Harigai M.

Immunol Med. 2018 Jun;41(2):75-81. doi: 10.1080/13497413.2018.1481578. Epub 2018 Sep 7.

PMID:
30938268
3.

Growing evidence of the safety of JAK inhibitors in patients with rheumatoid arthritis.

Harigai M.

Rheumatology (Oxford). 2019 Feb 1;58(Supplement_1):i34-i42. doi: 10.1093/rheumatology/key287.

4.

Safety profile of baricitinib in Japanese patients with active rheumatoid arthritis with over 1.6 years median time in treatment: An integrated analysis of Phases 2 and 3 trials.

Harigai M, Takeuchi T, Smolen JS, Winthrop KL, Nishikawa A, Rooney TP, Saifan CG, Issa M, Isaka Y, Akashi N, Ishii T, Tanaka Y.

Mod Rheumatol. 2019 Feb 20:1-8. doi: 10.1080/14397595.2019.1583711. [Epub ahead of print]

PMID:
30784354
5.

Association of MUC5B promoter polymorphism with interstitial lung disease in myeloperoxidase-antineutrophil cytoplasmic antibody-associated vasculitis.

Namba N, Kawasaki A, Sada KE, Hirano F, Kobayashi S, Yamada H, Furukawa H, Shimada K, Hashimoto A, Matsui T, Nagasaka K, Sugihara T, Suzuki A, Yamagata K, Sumida T, Tohma S, Homma S, Ozaki S, Hashimoto H, Makino H, Arimura Y, Harigai M, Tsuchiya N; Japan Research Committee of the Ministry of Health, Labour, and Welfare for Intractable Vasculitis (JPVAS).

Ann Rheum Dis. 2019 Aug;78(8):1144-1146. doi: 10.1136/annrheumdis-2018-214263. Epub 2019 Feb 14. No abstract available.

PMID:
30765393
6.

Molecular targeted therapies for microscopic polyangiitis and granulomatosis with polyangiitis.

Harigai M, Tsutsumino M, Takada H, Nagasaka K.

Korean J Intern Med. 2019 May;34(3):492-503. doi: 10.3904/kjim.2018.366. Epub 2019 Jan 9. Review.

7.

Higher risk of hospitalized infection, cardiovascular disease, and fracture in patients with rheumatoid arthritis determined using the Japanese health insurance database.

Kasai S, Sakai R, Koike R, Kohsaka H, Miyasaka N, Harigai M.

Mod Rheumatol. 2018 Nov 28:1-7. doi: 10.1080/14397595.2018.1519889. [Epub ahead of print] Erratum in: Mod Rheumatol. 2019 Apr 9;:1.

PMID:
30484352
8.

Development of the Asia Pacific Lupus Collaboration cohort.

Kandane-Rathnayake R, Golder V, Louthrenoo W, Luo SF, Jan Wu YJ, Li Z, An Y, Lateef A, Sockalingam S, Navarra SV, Zamora L, Hamijoyo L, Katsumata Y, Harigai M, Chan M, O'Neill S, Goldblatt F, Hao Y, Zhang Z, Al-Saleh J, Khamashta M, Takeuchi T, Tanaka Y, Bae SC, Lau CS, Hoi A, Nikpour M, Morand EF.

Int J Rheum Dis. 2019 Mar;22(3):425-433. doi: 10.1111/1756-185X.13431. Epub 2018 Nov 5.

PMID:
30398013
9.

Histopathological classification of anti-neutrophil cytoplasmic antibody-associated glomerulonephritis in a nationwide Japanese prospective 2-year follow-up cohort study.

Yamagata K, Usui J, Nagata M, Sugiyama H, Sada KE, Muso E, Harigai M, Amano K, Atsumi T, Fujimoto S, Yuzawa Y, Kobayashi M, Saito T, Ito T, Hirawa N, Homma S, Dobashi H, Tsuboi N, Ishizu A, Arimura Y, Makino H, Matsuo S; Research Committee of Intractable Renal Disease and the Research Committee of Intractable Vasculitis Syndrome of the Ministry of Health, Labour, and Welfare of Japan.

Clin Exp Nephrol. 2019 Mar;23(3):387-394. doi: 10.1007/s10157-018-1656-1. Epub 2018 Oct 10.

PMID:
30306344
10.

Safety and effectiveness of abatacept in Japanese non-elderly and elderly patients with rheumatoid arthritis in an all-cases post-marketing surveillance.

Harigai M, Ishiguro N, Inokuma S, Mimori T, Ryu J, Takei S, Takeuchi T, Tanaka Y, Takasaki Y, Yamanaka H, Yoshizawa Y, Chinen I, Nakao T, Koike T.

Mod Rheumatol. 2018 Oct 25:1-9. doi: 10.1080/14397595.2018.1524998. [Epub ahead of print]

PMID:
30217117
11.

2017 Clinical practice guidelines of the Japan Research Committee of the Ministry of Health, Labour, and Welfare for Intractable Vasculitis for the management of ANCA-associated vasculitis.

Harigai M, Nagasaka K, Amano K, Bando M, Dobashi H, Kawakami T, Kishibe K, Murakawa Y, Usui J, Wada T, Tanaka E, Nango E, Nakayama T, Tsutsumino M, Yamagata K, Homma S, Arimua Y.

Mod Rheumatol. 2019 Jan;29(1):20-30. doi: 10.1080/14397595.2018.1500437. Epub 2018 Sep 10.

PMID:
30001655
12.

Systematic review and meta-analysis for 2017 clinical practice guidelines of the Japan research committee of the ministry of health, labour, and welfare for intractable vasculitis for the management of ANCA-associated vasculitis.

Nagasaka K, Harigai M, Hagino N, Hara A, Horita T, Hayashi T, Itabashi M, Ito S, Katsumata Y, Kawashima S, Naniwa T, Sada KE, Nango E, Nakayama T, Tsutsumino M, Yamagata K, Homma S, Arimura Y.

Mod Rheumatol. 2019 Jan;29(1):119-129. doi: 10.1080/14397595.2018.1500111. Epub 2018 Sep 25.

PMID:
29996690
13.

Association Between Reappearance of Myeloperoxidase-Antineutrophil Cytoplasmic Antibody and Relapse in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Subgroup Analysis of Nationwide Prospective Cohort Studies.

Watanabe H, Sada KE, Matsumoto Y, Harigai M, Amano K, Dobashi H, Fujimoto S, Usui J, Yamagata K, Atsumi T, Banno S, Sugihara T, Arimura Y, Matsuo S, Makino H; Japan Research Committee of the Ministry of Health, Labour, and Welfare for Intractable Vasculitis, and the Research Committee of Intractable Renal Disease of the Ministry of Health, Labour, and Welfare of Japan.

Arthritis Rheumatol. 2018 Oct;70(10):1626-1633. doi: 10.1002/art.40538. Epub 2018 Aug 24.

PMID:
29790303
14.

Japan College of Rheumatology guideline for the use of methotrexate in patients with rheumatoid arthritis.

Kameda H, Fujii T, Nakajima A, Koike R, Sagawa A, Kanbe K, Tomita T, Harigai M, Suzuki Y; Japan College of Rheumatology subcommittee on the guideline for the use of methotrexate in patients with rheumatoid arthritis.

Mod Rheumatol. 2019 Jan;29(1):31-40. doi: 10.1080/14397595.2018.1472358. Epub 2018 May 24.

PMID:
29718746
15.

Can genetic studies predict treatment response in antineutrophil cytoplasmic antibody-associated vasculitis?

Harigai M.

Int J Rheum Dis. 2019 Jan;22 Suppl 1:95-99. doi: 10.1111/1756-185X.13294. Epub 2018 Apr 19. Review. No abstract available.

PMID:
29676040
16.

No increased risk of herpes zoster in TNF inhibitor and non-TNF inhibitor users with rheumatoid arthritis: epidemiological study using the Japanese health insurance database.

Sakai R, Kasai S, Hirano F, Harada S, Kihara M, Yokoyama W, Tsutsumino M, Nagasaka K, Koike R, Yamanaka H, Miyasaka N, Harigai M.

Int J Rheum Dis. 2018 Sep;21(9):1670-1677. doi: 10.1111/1756-185X.13300. Epub 2018 Apr 17.

PMID:
29667330
17.

Safety and effectiveness of iguratimod in patients with rheumatoid arthritis: Final report of a 52-week, multicenter postmarketing surveillance study.

Mimori T, Harigai M, Atsumi T, Fujii T, Kuwana M, Matsuno H, Momohara S, Takei S, Tamura N, Takasaki Y, Yamamoto K, Ikeuchi S, Kushimoto S, Koike T.

Mod Rheumatol. 2019 Mar;29(2):314-323. doi: 10.1080/14397595.2018.1460230. Epub 2018 Apr 27.

PMID:
29611761
18.

Efficacy and safety of sirukumab in Japanese patients with active rheumatoid arthritis who were refractory or intolerant to anti-tumor necrosis factor therapy: Subgroup analysis of a randomized, double-blind, multicenter, phase 3 study (SIRROUND-T).

Tanaka Y, Takeuchi T, Harigai M, Yamanaka H, Nakano T, Akagi K, Ukyo Y, Hsu B.

Mod Rheumatol. 2019 Mar;29(2):306-313. doi: 10.1080/14397595.2018.1452345. Epub 2018 Apr 13.

PMID:
29532734
19.

Low body mass index and lymphocytopenia associate with Mycobacterium avium complex pulmonary disease in patients with rheumatoid arthritis.

Hirose W, Harigai M, Uchiyama T, Itoh K, Ishizuka T, Matsumoto M, Nanki T.

Mod Rheumatol. 2019 Jan;29(1):105-112. doi: 10.1080/14397595.2018.1452334. Epub 2018 Apr 9.

PMID:
29532704
20.

Sirukumab in rheumatoid arthritis refractory to sulfasalazine or methotrexate: a randomized phase 3 safety and efficacy study in Japanese patients.

Takeuchi T, Yamanaka H, Harigai M, Tamamura R, Kato Y, Ukyo Y, Nakano T, Hsu B, Tanaka Y.

Arthritis Res Ther. 2018 Mar 7;20(1):42. doi: 10.1186/s13075-018-1536-9.

21.

Risk Factors for Relapse of Antineutrophil Cytoplasmic Antibody-associated Vasculitis in Japan: A Nationwide, Prospective Cohort Study.

Hara A, Wada T, Sada KE, Amano K, Dobashi H, Harigai M, Takasaki Y, Yamada H, Hasegawa H, Hayashi T, Fujimoto S, Muso E, Kawakami T, Homma S, Yoshida M, Hirahashi J, Ogawa N, Ito S, Makino H, Arimura Y; Research Committee on Intractable Vasculitides, and the Strategic Study Group to Establish the Evidence for Intractable Vasculitis Guideline.

J Rheumatol. 2018 Apr;45(4):521-528. doi: 10.3899/jrheum.170508. Epub 2018 Feb 1.

PMID:
29419469
22.

Efficacy and safety of sirukumab in Japanese patients with moderate to severe rheumatoid arthritis inadequately controlled by disease modifying anti-rheumatic drugs: Subgroup analysis of a phase 3 study.

Takeuchi T, Tanaka Y, Yamanaka H, Harigai M, Nakano T, Akagi K, Ukyo Y, Hsu B.

Mod Rheumatol. 2018 Nov;28(6):941-949. doi: 10.1080/14397595.2018.1428929. Epub 2018 Feb 7.

PMID:
29336187
23.

Clinical efficacy, radiographic, and safety results of golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior therapy with disease-modifying antirheumatic drugs: Final results of the GO-MONO trial through week 120.

Takeuchi T, Harigai M, Tanaka Y, Yamanaka H, Ishiguro N, Yamamoto K, Miyasaka N, Koike T, Ukyo Y, Ishii Y, Yoshinari T, Baker D; GO-MONO study group.

Mod Rheumatol. 2018 Sep;28(5):770-779. doi: 10.1080/14397595.2017.1404731. Epub 2017 Dec 8.

PMID:
29219638
24.

Association of ETS1 polymorphism with granulomatosis with polyangiitis and proteinase 3-anti-neutrophil cytoplasmic antibody positive vasculitis in a Japanese population.

Kawasaki A, Yamashita K, Hirano F, Sada KE, Tsukui D, Kondo Y, Kimura Y, Asako K, Kobayashi S, Yamada H, Furukawa H, Nagasaka K, Sugihara T, Yamagata K, Sumida T, Tohma S, Kono H, Ozaki S, Matsuo S, Hashimoto H, Makino H, Arimura Y, Harigai M, Tsuchiya N.

J Hum Genet. 2018 Jan;63(1):55-62. doi: 10.1038/s10038-017-0362-2. Epub 2017 Oct 5.

PMID:
29167552
25.

Efficacy and safety of baricitinib in Japanese patients with rheumatoid arthritis: Subgroup analyses of four multinational phase 3 randomized trials.

Tanaka Y, Atsumi T, Amano K, Harigai M, Ishii T, Kawaguchi O, Rooney TP, Akashi N, Takeuchi T.

Mod Rheumatol. 2018 Jul;28(4):583-591. doi: 10.1080/14397595.2017.1392057. Epub 2017 Nov 14.

PMID:
29134891
26.

Targeted proteomics reveals promising biomarkers of disease activity and organ involvement in antineutrophil cytoplasmic antibody-associated vasculitis.

Ishizaki J, Takemori A, Suemori K, Matsumoto T, Akita Y, Sada KE, Yuzawa Y, Amano K, Takasaki Y, Harigai M, Arimura Y, Makino H, Yasukawa M, Takemori N, Hasegawa H; Research Committee of Intractable Vasculitis Syndrome and the Research Committee of Intractable Renal Disease of the Ministry of Health, Labour and Welfare of Japan.

Arthritis Res Ther. 2017 Sep 29;19(1):218. doi: 10.1186/s13075-017-1429-3.

27.

Lymphoproliferative disorders in patients with rheumatoid arthritis in the era of widespread use of methotrexate: A review of the literature and current perspective.

Harigai M.

Mod Rheumatol. 2018 Jan;28(1):1-8. doi: 10.1080/14397595.2017.1352477. Epub 2017 Jul 31. Review.

PMID:
28758827
28.

Prediction of response to remission induction therapy by gene expression profiling of peripheral blood in Japanese patients with microscopic polyangiitis.

Ishizu A, Tomaru U, Masuda S, Sada KE, Amano K, Harigai M, Kawaguchi Y, Arimura Y, Yamagata K, Ozaki S, Dobashi H, Homma S, Okada Y, Sugiyama H, Usui J, Tsuboi N, Matsuo S, Makino H; Research Committee of the Intractable Vasculitis Syndrome and the Research Committee of the Intractable Renal Disease of the Ministry of Health, Labour, and Welfare of Japan.

Arthritis Res Ther. 2017 May 31;19(1):117. doi: 10.1186/s13075-017-1328-7.

29.

Consensus statements for medical practice: Biological agents and lung disease [Abridged English translation by the Japanese Respiratory Society].

Tokuda H, Harigai M, Kameda H, Tomono K, Takayanagi N, Watanabe A, Tasaka S, Suda T, Tateda K, Kadota J.

Respir Investig. 2017 May;55(3):229-251. doi: 10.1016/j.resinv.2017.01.002. Epub 2017 Mar 29. Review. No abstract available.

PMID:
28427750
30.

Association Between Medications and Herpes Zoster in Japanese Patients with Rheumatoid Arthritis: A 5-year Prospective Cohort Study.

Harada S, Sakai R, Hirano F, Miyasaka N, Harigai M; REAL Study Group.

J Rheumatol. 2017 Jul;44(7):988-995. doi: 10.3899/jrheum.161196. Epub 2017 Apr 15.

PMID:
28412701
31.

Long-term safety and effectiveness of adalimumab for the treatment of Japanese patients with rheumatoid arthritis: 3-year results from a postmarketing surveillance of 552 patients.

Harigai M, Tsuchiya T, Kawana K, Kurimoto S.

Mod Rheumatol. 2018 Jan;28(1):30-38. doi: 10.1080/14397595.2017.1304159. Epub 2017 Apr 7.

PMID:
28388293
32.

Optimal regimens of sulfamethoxazole-trimethoprim for chemoprophylaxis of Pneumocystis pneumonia in patients with systemic rheumatic diseases: results from a non-blinded, randomized controlled trial.

Utsunomiya M, Dobashi H, Odani T, Saito K, Yokogawa N, Nagasaka K, Takenaka K, Soejima M, Sugihara T, Hagiyama H, Hirata S, Matsui K, Nonomura Y, Kondo M, Suzuki F, Tomita M, Kihara M, Yokoyama W, Hirano F, Yamazaki H, Sakai R, Nanki T, Koike R, Kohsaka H, Miyasaka N, Harigai M.

Arthritis Res Ther. 2017 Jan 18;19(1):7. doi: 10.1186/s13075-016-1206-8.

33.

Safety and effectiveness of 24-week treatment with iguratimod, a new oral disease-modifying antirheumatic drug, for patients with rheumatoid arthritis: interim analysis of a post-marketing surveillance study of 2679 patients in Japan.

Mimori T, Harigai M, Atsumi T, Fujii T, Kuwana M, Matsuno H, Momohara S, Takei S, Tamura N, Takasaki Y, Ikeuchi S, Kushimoto S, Koike T.

Mod Rheumatol. 2017 Sep;27(5):755-765. doi: 10.1080/14397595.2016.1265695. Epub 2016 Dec 21. Erratum in: Mod Rheumatol. 2017 Sep;27(5):v.

PMID:
27919207
34.

Achieving simplified disease activity index remission in patients with active rheumatoid arthritis is associated with subsequent good functional and structural outcomes in a real-world clinical setting under a treat-to-target strategy.

Hirano F, Yokoyama W, Yamazaki H, Amano K, Kawakami A, Hayashi T, Tamura N, Yasuda S, Dobashi H, Fujii T, Ito S, Kaneko Y, Matsui T, Okuda Y, Saito K, Suzuki F, Yoshimi R, Sakai R, Koike R, Kohsaka H, Miyasaka N, Harigai M; T2T Epidemiological Study Group.

Mod Rheumatol. 2017 Sep;27(5):811-819. doi: 10.1080/14397595.2016.1265726. Epub 2016 Dec 21.

PMID:
27919205
35.

Simplified Disease Activity Index remission at month 6 is an independent predictor of functional and structural remissions at month 12 during abatacept treatment in patients with rheumatoid arthritis: A multi-center, prospective cohort study in Japan.

Yamazaki H, Hirano F, Takeuchi T, Amano K, Kikuchi J, Kihara M, Yokoyama W, Sugihara T, Nagasaka K, Hagiyama H, Nonomura Y, Sakai R, Tanaka M, Koike R, Nanki T, Kohsaka H, Miyasaka N, Harigai M.

Mod Rheumatol. 2017 Sep;27(5):787-794. doi: 10.1080/14397595.2016.1259715. Epub 2016 Dec 15.

PMID:
27846756
36.

Effect of Methotrexate Plus Adalimumab on the Achievement of Rheumatoid Arthritis Therapeutic Goals: Post Hoc Analysis of Japanese Patients (MELODY Study).

Koike T, Harigai M, Ishiguro N, Inokuma S, Takei S, Takeuchi T, Yamanaka H, Takasaki Y, Mimori T, Hiramatsu K, Komatsu S, Tanaka Y.

Rheumatol Ther. 2016 Jun;3(1):129-141. doi: 10.1007/s40744-015-0023-x. Epub 2015 Dec 22.

37.

Effects of immunosuppressive and biological agents on refractory Takayasu arteritis patients unresponsive to glucocorticoid treatment.

Ohigashi H, Tamura N, Ebana Y, Harigai M, Maejima Y, Ashikaga T, Isobe M.

J Cardiol. 2017 May;69(5):774-778. doi: 10.1016/j.jjcc.2016.07.009. Epub 2016 Aug 25.

38.

Clinical characteristics of and risk factors for serious infection in Japanese patients within six months of remission induction therapy for antineutrophil cytoplasmic antibody-associated vasculitis registered in a nationwide, prospective, inception cohort study.

Watanabe-Imai K, Harigai M, Sada KE, Yamamura M, Fujii T, Dobashi H, Amano K, Ito S, Homma S, Kumagai S, Banno S, Arimura Y, Makino H; Research Committee on Intractable Vasculitides, the Ministry of Health, Labor and Welfare of Japan.

Mod Rheumatol. 2017 Jul;27(4):646-651. doi: 10.1080/14397595.2016.1226468. Epub 2016 Oct 10.

PMID:
27538706
39.

Effectiveness and safety of tocilizumab in achieving clinical and functional remission, and sustaining efficacy in biologics-naive patients with rheumatoid arthritis: The FIRST Bio study.

Ishiguro N, Atsumi T, Harigai M, Mimori T, Nishimoto N, Sumida T, Takeuchi T, Tanaka Y, Nakasone A, Takagi N, Yamanaka H.

Mod Rheumatol. 2017 Mar;27(2):217-226. doi: 10.1080/14397595.2016.1206507. Epub 2016 Jul 14.

PMID:
27414105
40.
41.

Protective Role of HLA-DRB1*13:02 against Microscopic Polyangiitis and MPO-ANCA-Positive Vasculitides in a Japanese Population: A Case-Control Study.

Kawasaki A, Hasebe N, Hidaka M, Hirano F, Sada KE, Kobayashi S, Yamada H, Furukawa H, Yamagata K, Sumida T, Miyasaka N, Tohma S, Ozaki S, Matsuo S, Hashimoto H, Makino H, Arimura Y, Harigai M, Tsuchiya N.

PLoS One. 2016 May 11;11(5):e0154393. doi: 10.1371/journal.pone.0154393. eCollection 2016.

42.

Tacrolimus successfully used to control refractory eosinophilic granulomatosis with polyangiitis complicated by invasive aspergillosis and chronic hepatitis B.

Hirano F, Mizoguchi F, Harigai M, Miyasaka N, Kohsaka H.

Int J Rheum Dis. 2019 Apr;22(4):746-749. doi: 10.1111/1756-185X.12869. Epub 2016 Apr 29.

PMID:
27125472
43.

Risk for malignancy in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs compared to the general population: A nationwide cohort study in Japan.

Harigai M, Nanki T, Koike R, Tanaka M, Watanabe-Imai K, Komano Y, Sakai R, Yamazaki H, Koike T, Miyasaka N.

Mod Rheumatol. 2016 Sep;26(5):642-50. doi: 10.3109/14397595.2016.1141740. Epub 2016 Mar 11.

PMID:
26873430
44.

Comparison of severity classification in Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis in a nationwide, prospective, inception cohort study.

Sada KE, Harigai M, Amano K, Atsumi T, Fujimoto S, Yuzawa Y, Takasaki Y, Banno S, Sugihara T, Kobayashi M, Usui J, Yamagata K, Homma S, Dobashi H, Tsuboi N, Ishizu A, Sugiyama H, Okada Y, Arimura Y, Matsuo S, Makino H; for Research Committee of Intractable Vasculitis Syndrome and Research Committee of Intractable Renal Disease of the Ministry of Health, Labour, and Welfare of Japan.

Mod Rheumatol. 2016 Sep;26(5):730-7. doi: 10.3109/14397595.2016.1140274. Epub 2016 Mar 11.

PMID:
26873424
45.
46.

Nationwide prospective and retrospective surveys for hepatitis B virus reactivation during immunosuppressive therapies.

Mochida S, Nakao M, Nakayama N, Uchida Y, Nagoshi S, Ido A, Mimura T, Harigai M, Kaneko H, Kobayashi H, Tsuchida T, Suzuki H, Ura N, Nakamura Y, Bessho M, Dan K, Kusumoto S, Sasaki Y, Fujii H, Suzuki F, Ikeda K, Yamamoto K, Takikawa H, Tsubouchi H, Mizokami M.

J Gastroenterol. 2016 Oct;51(10):999-1010. doi: 10.1007/s00535-016-1168-2. Epub 2016 Feb 1.

PMID:
26831356
47.

High prevalence of cardiovascular comorbidities in patients with rheumatoid arthritis from a population-based cross-sectional study of a Japanese health insurance database.

Sakai R, Hirano F, Kihara M, Yokoyama W, Yamazaki H, Harada S, Nanki T, Koike R, Miyasaka N, Harigai M.

Mod Rheumatol. 2016 Jul;26(4):522-8. doi: 10.3109/14397595.2015.1106682. Epub 2015 Dec 14.

PMID:
26666766
48.

Postmarketing surveillance of the safety and effectiveness of abatacept in Japanese patients with rheumatoid arthritis.

Harigai M, Ishiguro N, Inokuma S, Mimori T, Ryu J, Takei S, Takeuchi T, Tanaka Y, Takasaki Y, Yamanaka H, Watanabe M, Tamada H, Koike T.

Mod Rheumatol. 2016 Jul;26(4):491-8. doi: 10.3109/14397595.2015.1123211. Epub 2016 Jan 8.

49.

Psychological distress in corticosteroid-naive patients with systemic lupus erythematosus: A prospective cross-sectional study.

Nishimura K, Omori M, Katsumata Y, Sato E, Kawaguchi Y, Harigai M, Yamanaka H, Ishigooka J.

Lupus. 2016 Apr;25(5):463-71. doi: 10.1177/0961203315615223. Epub 2015 Nov 1.

PMID:
26527504
50.

Different responses to treatment across classified diseases and severities in Japanese patients with microscopic polyangiitis and granulomatosis with polyangiitis: a nationwide prospective inception cohort study.

Sada KE, Yamamura M, Harigai M, Fujii T, Takasaki Y, Amano K, Fujimoto S, Muso E, Murakawa Y, Arimura Y, Makino H; Research Committee on Intractable Vasculitides, the Ministry of Health, Labour and Welfare of Japan.

Arthritis Res Ther. 2015 Nov 2;17:305. doi: 10.1186/s13075-015-0815-y.

Supplemental Content

Loading ...
Support Center